ERBB2 and lung carcinoma: Our case provides evidence that HER2-mutant lung cancer could benefit from chemoimmunotherapy treatment, although the oligometastatic stage, amenable to integrated treatments, and the high PD-L1 expression may have contributed to the exceptional response observed.